U.S. regulators on Monday approved #Biogen Inc's aducanumab as the first treatment to attack a likely cause of #Alzheimer's disease despite controversy over whether the #clinical evidence proves the #drug works, sending its shares soaring. Subscribe to France 24 now: http://f24.my/youtubeEN FRANCE 24 live news stream: all the latest news 24/7 http://f24.my/YTliveEN Visit our website: http://www.france24.com Subscribe to our YouTube channel: http://f24.my/youtubeEN Like us on Facebook: / france24.english Follow us on Twitter: / france24_en